Andexanet alfa (Andexxa) will leave the US market on December 22, 2025, after AstraZeneca withdrew its biologics license application for commercial reasons. For a drug that costs as much as a car (~$25-50K per dose) and carries meaningful safety concerns… good riddance!
Andexanet entered practice as the only FDA-approved reversal agent specifically targeting factor Xa inhibitors. At the same time, four-factor PCC (like KCentra) remained the familiar off-label alternative already embedded in most hospital workflows.
The American College of Cardiology has favored andexanet when available, primarily based on the ANNEXA-4 trial, which showed rapid and significant reductions in anti-factor Xa activity and acceptable hemostatic efficacy in major bleeding, particularly intracranial hemorrhage. Anti-factor Xa levels fell by more than ninety percent within minutes, and most patients achieved good or excellent hemostasis. In contrast, evidence for four-factor PCC in Xa inhibitor reversal is indirect, drawn from small observational cohorts and extrapolated dosing strategies rather than prospective trials.
Despite these impressive results, comparative effectiveness studies have blurred any clear advantage. Some propensity weighted and VA analyses suggest higher hemostatic success and possibly lower short-term mortality with andexanet in selected patients, but these differences often disappear after accounting for baseline neurologic severity. Thrombotic risk (e.g., ischemic stroke) remains the central concern, with consistently higher event rates reported with andexanet compared to PCC, especially when anticoagulation is not restarted. With Andexxa gone, most systems will default to PCC; however, the decision to reverse anticoagulation still requires careful patient selection and a clear plan to resume anticoagulation.
Here are some PubMed IDs to review the data: 30730782, 36802876, 38749032, 27573206, 41208947
Leave a Reply